サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1164613

HPV検査・パップテストの世界市場：検査の種類別 (HPV検査 (フォローアップHPV検査、併用検査、一次HPV検査)、パップテスト)・エンドユーザー別 (検査施設、病院、開業医・診療所)・地域別の将来予測 (2027年まで)

HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co- Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 181 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
HPV検査・パップテストの世界市場：検査の種類別 (HPV検査 (フォローアップHPV検査、併用検査、一次HPV検査)、パップテスト)・エンドユーザー別 (検査施設、病院、開業医・診療所)・地域別の将来予測 (2027年まで)
出版日: 2022年11月25日
発行: MarketsandMarkets
ページ情報: 英文 181 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のHPV (ヒトパピローマウイルス) 検査・パップテストの市場規模は、2022年の49億米ドルから2027年には92億米ドルに達し、予測期間に13.2%のCAGRで成長すると予測されています。

市場成長の背景には、HPV診断製品の増産や政府の取り組みといった要因があります。一方、不透明な償還シナリオがなどが、この市場の成長を阻害する主な要因となっています。

"検査の種類別ではにHPV検査のセグメントが最も高い成長率を占める"

検査の種類別では2021年に、HPV検査分野が最も高い成長率を占めました。製品承認数の増加や、がん患者数の減少に向けた取り組みの強化が、同分野の成長に寄与する主な要因となっています。

"用途別では、子宮頸がん検診のセグメントが最も高い成長率を占める"

用途別では2021年に、子宮頸がん検診の分野が最も高い成長率を占めています。子宮頸がん予防のための資金調達の増加は、このセグメントの成長に寄与する主要な要因です。

"エンドユーザー別では、病院セグメントが最も高い成長率を占める"

エンドユーザー別では2021年に、病院セグメントが最も高い成長率を占めました。新興国市場が有利な成長機会を提供していることが、このセグメントの成長に寄与している主な要因です。

"アジア太平洋：最も成長率の高い地域"

地域別に見ると、アジア太平洋地域が予測期間中に最も高いCAGRを記録すると予測されています。子宮頸がんに対する意識付けに焦点を当てた会議の増加が、この地域の市場成長を促進しています。

当レポートでは、世界のHPV検査・パップテストの市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、検査の種類別・用途別・エンドユーザー別・地域別の市場動向の見通し、市場競争の状態、主要企業のプロファイルなどを調査しております。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 価格分析
  • 特許分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム/マーケットマップ
  • ポーターのファイブフォース分析
  • 貿易分析
    • 診断用・実験用試薬の貿易分析
  • 顧客のビジネスに影響を与える動向/混乱

第6章 HPV検査・パップテスト市場：検査の種類別

  • イントロダクション
  • HPV検査
    • フォローアップHPV検査
    • 併用検査
    • 一次HPV検査
  • パップテスト

第7章 HPV検査・パップテスト市場：用途別

  • イントロダクション
  • 子宮頸がん検診
  • 膣がん検診

第8章 HPV検査・パップテスト市場：エンドユーザー別

  • イントロダクション
  • 病院
  • 検査施設
  • 開業医・診療所

第9章 HPV検査・パップテスト市場：地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • 他の欧州諸国
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 他のアジア太平洋諸国
  • ラテンアメリカ
  • 中東・アフリカ

第10章 競合情勢

  • 概要
  • 主要企業が採用した戦略
  • 主要企業の収益シェア分析
  • 市場シェア分析
  • 企業評価クアドラント
  • スタートアップ/中小企業向けの競合リーダーシップ・マッピング (2021年)
  • 競合シナリオ
    • 製品の発売と承認
    • 資本取引
    • その他の動向

第11章 企業プロファイル

  • 主要企業
    • ABBOTT LABORATORIES
    • ROCHE DIAGNOSTICS
    • HOLOGIC, INC.
    • BECTON, DICKINSON AND COMPANY
    • QUEST DIAGNOSTICS
    • QIAGEN N.V.
    • SEEGENE, INC.
    • FEMASYS, INC.
    • ARBOR VITA CORPORATION
    • MYLAB DISCOVERY SOLUTIONS PVT. LTD.
  • その他の企業
    • EVERLYWELL INC.
    • NURX INC.
    • DALRADA CORPORATION
    • NEODIAGNOSTIX
    • JIANGSU MOLE BIOSCIENCE CO., LTD.
    • SANSURE BIOTECH INC.

第12章 付録

目次
Product Code: MD 4083

The global HPV testing and Pap test market is projected to reach USD 9.2 billion by 2027 from USD 4.9 billion in 2022, at a CAGR of 13.2% during the forecast period. Market growth is driven by factors such as increased production HPV diagnostic products and government initiatives. On the other hand, challenges associated with HPV testing and Pap test is uncertain reimbursement scenarios is the major factors hampering the growth of this market.

"The HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market, by test type, during the forecast period"

The HPV testing and Pap test market is segmented into HPV testing and Pap test. In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market. Increase in number of product approval and increased focus on reducing cancer cases are major factor contributing to the growth of this segment.

"The cervical cancer screening segment accounted for the highest growth rate in the HPV testing and Pap test market, by application, during the forecast period"

The HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market. Increasing funding for the prevention of cervical cancer are major factor contributing to the growth of this segment.

"The hospitals segment accounted for the highest growth rate in the HPV testing and Pap test market, by end user, during the forecast period"

The HPV testing and Pap test market is segmented into laboratories, hospitals and physician's offices & clinics based on end user. In 2021, the hospitals segment accounted for the highest growth rate in the HPV testing and Pap test market. Emerging markets offer lucrative growth opportunities are major factors contributing to the growth of this segment.

"Asia Pacific: The fastest-growing region in HPV testing and Pap test market"

The global HPV testing and Pap test market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Increasing number of conferences focused on creating awareness of cervical cancer is driving the growth of the HPV testing and Pap test market in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa - 4%

Lists of Companies Profiled in the Report:

  • Abbott Laboratories (US)
  • Roche Diagnostics (Switzerland)
  • Becton, Dickinson and Company (US)
  • Hologic, Inc. (US)
  • Quest Diagnostics (US)
  • Qiagen N.V. (Netherland)
  • Seegene, Inc. (US)
  • Femasys, Inc. (US)
  • Arbor Vita Corporation (US)
  • Mylab Discovery Solutions Pvt. Ltd. (India)
  • EverlyWell, Inc. (US)
  • Nurx, Inc. (US)
  • Dalrada Corporation (US)
  • NeoDiagnostix (US)
  • Jiangsu Mole Bioscience Co., Ltd. (China)
  • Sansure Biotech Inc. (China)

Research Coverage:

This report provides a detailed picture of the global HPV testing and Pap test market. It aims at estimating the size and future growth potential of the market across different segments, such as test type, application, end user and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall HPV testing and Pap test market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKETS COVERED
    • FIGURE 1 HPV TESTING AND PAP TEST MARKET SEGMENTATION
    • 1.3.1 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 2 HPV TESTING AND PAP TEST MARKET: RESEARCH DESIGN
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 CAGR projections
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 7 HPV TESTING AND PAP TEST MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 GROWTH RATE ASSUMPTIONS
  • 2.8 RISK ASSESSMENT
    • 2.8.1 HPV TESTING AND PAP TEST MARKET: RISK ASSESSMENT

3 EXECUTIVE SUMMARY

    • FIGURE 9 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 10 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 HPV TESTING AND PAP TEST MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 HPV TESTING AND PAP TEST MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 HPV TESTING AND PAP TEST MARKET OVERVIEW
    • FIGURE 13 RISING CASES OF HPV AND INCREASING R&D INITIATIVES ON CERVICAL CANCER SCREENING TO DRIVE MARKET
  • 4.2 HPV TESTING AND PAP TEST MARKET SHARE, BY TEST TYPE, 2022 VS. 2027
    • FIGURE 14 HPV TESTING SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.3 HPV TESTING AND PAP TEST MARKET SHARE, BY APPLICATION, 2022 VS. 2027
    • FIGURE 15 CERVICAL CANCER SCREENING SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 HPV TESTING AND PAP TEST MARKET SHARE, BY END USER, 2022 VS. 2027
    • FIGURE 16 HOSPITALS TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
  • 4.5 HPV TESTING AND PAP TEST MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 HPV TESTING AND PAP TEST MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising HPV cases and subsequent increase in cervical cancer
      • 5.2.1.2 Growing awareness of cervical cancer screening programs
      • 5.2.1.3 Increasing R&D funding initiatives on cervical cancer prevention
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Growing awareness of HPV vaccination
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Regulatory guidelines for cervical cancer screening
      • 5.2.3.2 Innovative improvements in HPV tests
        • 5.2.3.2.1 Introduction of HPV primary screening tests
        • 5.2.3.2.2 Technological improvements in HPV tests
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Uncertain reimbursement scenario
      • 5.2.4.2 Stringent regulatory & legal requirements
      • 5.2.4.3 Operational barriers
  • 5.3 PRICING ANALYSIS
    • TABLE 1 PRICE OF HPV TESTING AND PAP TEST PRODUCTS (2021)
  • 5.4 PATENT ANALYSIS
    • FIGURE 19 PATENT ANALYSIS OF HPV TESTING AND PAP TEST MARKET
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 20 VALUE CHAIN ANALYSIS OF HPV TESTING AND PAP TEST MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 21 HPV TESTING AND PAP TEST MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM/MARKET MAP
    • FIGURE 22 HPV TESTING AND PAP TEST MARKET: ECOSYSTEM/MARKET MAP
    • 5.7.1 HPV TESTING AND PAP TEST MARKET: ROLE IN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 2 HPV TESTING AND PAP TEST MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 DEGREE OF COMPETITION
  • 5.9 TRADE ANALYSIS
    • 5.9.1 TRADE ANALYSIS FOR DIAGNOSTIC OR LABORATORY REAGENTS
    • TABLE 3 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (USD MILLION)
    • TABLE 4 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (USD MILLION)
  • 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 5.10.1 REVENUE SOURCES SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19
    • FIGURE 23 REVENUE SHIFT IN HPV TESTING AND PAP TEST MARKET

6 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE

  • 6.1 INTRODUCTION
    • TABLE 5 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 6 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 7 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (MILLION KITS)
    • TABLE 8 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (MILLION KITS)
  • 6.2 HPV TESTING
    • TABLE 9 HPV TESTING MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 10 HPV TESTING MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 11 HPV TESTING MARKET, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 12 HPV TESTING MARKET, BY REGION, 2021-2027 (USD MILLION)
    • 6.2.1 FOLLOW-UP HPV TESTING
      • 6.2.1.1 Irregular Pap test results to drive adoption
    • TABLE 13 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 14 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2021-2027 (USD MILLION)
    • 6.2.2 CO-TESTING
      • 6.2.2.1 Co-testing to drive rapid detection results for cervical cancer
    • TABLE 15 HPV CO-TESTING MARKET, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 16 HPV CO-TESTING MARKET, BY REGION, 2021-2027 (USD MILLION)
    • 6.2.3 PRIMARY HPV TESTING
      • 6.2.3.1 Test sensitivity and accuracy to drive segment growth
    • TABLE 17 PRIMARY HPV TESTING MARKET, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 18 PRIMARY HPV TESTING MARKET, BY REGION, 2021-2027 (USD MILLION)
  • 6.3 PAP TEST
    • 6.3.1 RISING CASES OF FALSE-NEGATIVE TESTS TO RESTRAIN MARKET
    • TABLE 19 PAP TEST MARKET, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 20 PAP TEST MARKET, BY REGION, 2021-2027 (USD MILLION)

7 HPV TESTING AND PAP TEST MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 21 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 22 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
  • 7.2 CERVICAL CANCER SCREENING
    • 7.2.1 RISING INCIDENCE OF CERVICAL CANCER TO DRIVE MARKET
    • TABLE 23 HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 24 HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2021-2027 (USD MILLION)
  • 7.3 VAGINAL CANCER SCREENING
    • 7.3.1 LIMITED SCREENING TESTS TO RESTRAIN MARKET
    • TABLE 25 HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 26 HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2021-2027 (USD MILLION)

8 HPV TESTING AND PAP TEST MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 27 HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 28 HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
  • 8.2 HOSPITALS
    • 8.2.1 ADVANCED TECHNOLOGIES AND EQUIPPED FACILITIES TO DRIVE MARKET
    • TABLE 29 HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 30 HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2021-2027 (USD MILLION)
  • 8.3 LABORATORIES
    • 8.3.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO LABORATORIES TO DRIVE MARKET
    • TABLE 31 HPV TESTING AND PAP TEST MARKET FOR LABORATORIES, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 32 HPV TESTING AND PAP TEST MARKET FOR LABORATORIES, BY REGION, 2021-2027 (USD MILLION)
  • 8.4 PHYSICIANS' OFFICES AND CLINICS
    • 8.4.1 RAPID AND EFFICIENT RESULTS TO SUPPORT MARKET GROWTH
    • TABLE 33 HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES AND CLINICS, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 34 HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS' OFFICES AND CLINICS, BY REGION, 2021-2027 (USD MILLION)

9 HPV TESTING AND PAP TEST MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 35 HPV TESTING AND PAP TEST MARKET, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 36 HPV TESTING AND PAP TEST MARKET, BY REGION, 2021-2027 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 24 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SNAPSHOT
    • TABLE 37 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 38 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2021-2027 (USD MILLION)
    • TABLE 39 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 40 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 41 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (MILLION KITS)
    • TABLE 42 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (MILLION KITS)
    • TABLE 43 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 44 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 45 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 46 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 47 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 48 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Rising government initiatives for cancer research to drive market
    • TABLE 49 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 50 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 51 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (MILLION KITS)
    • TABLE 52 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (MILLION KITS)
    • TABLE 53 US: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 54 US: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 55 US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 56 US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 57 US: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 58 US: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Government support in raising awareness on cervical cancer screening to support market growth
    • TABLE 59 CANADA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 60 CANADA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 61 CANADA: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 62 CANADA: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 63 CANADA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 64 CANADA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 65 CANADA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 66 CANADA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
  • 9.3 EUROPE
    • TABLE 67 EUROPE: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 68 EUROPE: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2021-2027 (USD MILLION)
    • TABLE 69 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 70 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 71 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (MILLION KITS)
    • TABLE 72 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (MILLION KITS)
    • TABLE 73 EUROPE: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 74 EUROPE: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 75 EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 76 EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 77 EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 78 EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Established healthcare infrastructure and rising government spending on cancer screening to drive market
    • TABLE 79 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 80 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 81 GERMANY: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 82 GERMANY: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 83 GERMANY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 84 GERMANY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 85 GERMANY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 86 GERMANY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Rising focus on research projects for specific cancers to drive market
    • TABLE 87 UK: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 88 UK: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 89 UK: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 90 UK: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 91 UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 92 UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 93 UK: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 94 UK: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 High incidence of cervical cancer and associated investments in genomics to support market growth
    • TABLE 95 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 96 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 97 FRANCE: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 98 FRANCE: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 99 FRANCE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 100 FRANCE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 101 FRANCE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 102 FRANCE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.3.4 SPAIN
      • 9.3.4.1 Increasing research on cancer diagnostics to support market growth
    • TABLE 103 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 104 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 105 SPAIN: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 106 SPAIN: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 107 SPAIN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 108 SPAIN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 109 SPAIN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 110 SPAIN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.3.5 ITALY
      • 9.3.5.1 Growing acceptance of molecular-based diagnostic tests for cervical cancer screening to drive market
    • TABLE 111 ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 112 ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 113 ITALY: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 114 ITALY: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 115 ITALY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 116 ITALY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 117 ITALY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 118 ITALY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 119 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 120 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 121 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 122 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 123 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 124 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 125 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 126 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 25 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET SNAPSHOT
    • TABLE 127 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 128 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2021-2027 (USD MILLION)
    • TABLE 129 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 130 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 131 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (MILLION KITS)
    • TABLE 132 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (MILLION KITS)
    • TABLE 133 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 134 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 135 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 Government initiatives for cancer diagnosis and immunotherapy to support market growth
    • TABLE 139 CHINA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 140 CHINA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 141 CHINA: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 142 CHINA: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 143 CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 144 CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 145 CHINA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 146 CHINA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Rising demand for technologically advanced cervical cancer screening tests to drive market
    • TABLE 147 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 148 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 149 JAPAN: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 150 JAPAN: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 151 JAPAN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 152 JAPAN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 153 JAPAN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 154 JAPAN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 High cancer burden and rising pharmaceutical industry to drive market
    • TABLE 155 INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 156 INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 157 INDIA: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 158 INDIA: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 159 INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 160 INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 161 INDIA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 162 INDIA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 163 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 164 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 165 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 166 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 167 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 168 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 169 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 170 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
  • 9.5 LATIN AMERICA
    • 9.5.1 RISING AWARENESS OF ADVANCED CANCER SCREENING TECHNOLOGIES TO DRIVE MARKET
    • TABLE 171 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 172 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 173 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (MILLION KITS)
    • TABLE 174 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (MILLION KITS)
    • TABLE 175 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 176 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 177 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 178 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 179 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 180 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)
  • 9.6 MIDDLE EAST AND AFRICA
    • 9.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE DUE TO HIGH CANCER BURDEN TO SUPPORT MARKET GROWTH
    • TABLE 181 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (USD MILLION)
    • TABLE 182 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (USD MILLION)
    • TABLE 183 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017-2020 (MILLION KITS)
    • TABLE 184 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021-2027 (MILLION KITS)
    • TABLE 185 MIDDLE EAST AND AFRICA: HPV TESTING MARKET, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 186 MIDDLE EAST AND AFRICA: HPV TESTING MARKET, BY TYPE, 2021-2027 (USD MILLION)
    • TABLE 187 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017-2020 (USD MILLION)
    • TABLE 188 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021-2027 (USD MILLION)
    • TABLE 189 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 190 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021-2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • 10.2.1 HPV TESTING AND PAP TEST MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 191 OVERVIEW OF STRATEGIES ADOPTED BY KEY HPV TESTING AND PAP TEST PLAYERS
  • 10.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
    • FIGURE 26 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
  • 10.4 MARKET SHARE ANALYSIS
    • FIGURE 27 HPV TESTING AND PAP TEST MARKET SHARE, BY KEY PLAYER (2021)
    • TABLE 192 HPV TESTING AND PAP TEST MARKET: DEGREE OF COMPETITION
  • 10.5 COMPANY EVALUATION QUADRANT
    • 10.5.1 LIST OF EVALUATED VENDORS
    • 10.5.2 STARS
    • 10.5.3 EMERGING LEADERS
    • 10.5.4 PERVASIVE PLAYERS
    • 10.5.5 PARTICIPANTS
    • FIGURE 28 HPV TESTING AND PAP TEST MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
  • 10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 STARTING BLOCKS
    • 10.6.3 RESPONSIVE COMPANIES
    • 10.6.4 DYNAMIC COMPANIES
    • FIGURE 29 HPV TESTING AND PAP TEST MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
  • 10.7 COMPETITIVE SCENARIO
    • 10.7.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 193 PRODUCT LAUNCHES & APPROVALS (2020-2022)
    • 10.7.2 DEALS
    • TABLE 194 DEALS (2021-2022)
    • 10.7.3 OTHER DEVELOPMENTS
    • TABLE 195 OTHER DEVELOPMENTS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
    • 11.1.1 ABBOTT LABORATORIES
    • TABLE 196 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 30 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
    • 11.1.2 ROCHE DIAGNOSTICS
    • TABLE 197 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 31 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021)
    • 11.1.3 HOLOGIC, INC.
    • TABLE 198 HOLOGIC, INC.: BUSINESS OVERVIEW
    • FIGURE 32 HOLOGIC, INC: COMPANY SNAPSHOT (2021)
    • 11.1.4 BECTON, DICKINSON AND COMPANY
    • TABLE 199 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
    • 11.1.5 QUEST DIAGNOSTICS
    • TABLE 200 QUEST DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 34 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2021)
    • 11.1.6 QIAGEN N.V.
    • TABLE 201 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
    • 11.1.7 SEEGENE, INC.
    • TABLE 202 SEEGENE, INC: BUSINESS OVERVIEW
    • 11.1.8 FEMASYS, INC.
    • TABLE 203 FEMASYS, INC.: BUSINESS OVERVIEW
    • 11.1.9 ARBOR VITA CORPORATION
    • TABLE 204 ARBOR VITA CORPORATION: BUSINESS OVERVIEW
    • 11.1.10 MYLAB DISCOVERY SOLUTIONS PVT. LTD.
    • TABLE 205 MYLAB DISCOVERY SOLUTIONS PVT. LTD.: BUSINESS OVERVIEW
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
  • 11.2 OTHER PLAYERS
    • 11.2.1 EVERLYWELL INC.
    • TABLE 206 EVERLYWELL INC.: COMPANY OVERVIEW
    • 11.2.2 NURX INC.
    • TABLE 207 NURX INC.: COMPANY OVERVIEW
    • 11.2.3 DALRADA CORPORATION
    • TABLE 208 DALRADA CORPORATION: COMPANY OVERVIEW
    • 11.2.4 NEODIAGNOSTIX
    • TABLE 209 NEODIAGNOSTIX: COMPANY OVERVIEW
    • 11.2.5 JIANGSU MOLE BIOSCIENCE CO., LTD.
    • TABLE 210 JIANGSU MOLE BIOSCIENCE CO., LTD.: COMPANY OVERVIEW
    • 11.2.6 SANSURE BIOTECH INC.
    • TABLE 211 SANSURE BIOTECH, INC.: COMPANY OVERVIEW

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS